Navigating the Evolving Treatment Landscape in HER2-mutated NSCLC - Episode 4

DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC

, , , ,

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Diagnosing HER2-mutated NSCLC
    EP. 2: Biomarker Testing Challenges in HER2-mutated NSCLC
    EP. 3: Role of ADCs in HER2-Mutated NSCLC
    Now Viewing
    EP. 4: DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC
    EP. 5: The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC
    EP. 6: DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC
    EP. 7: Managing Adverse Events Associated With ADCs in HER2-Mutated NSCLC
    EP. 8: The Potential Role of TKIs in HER2-Mutated NSCLC
    EP. 9: Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC
    EP. 10: First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC
    EP. 11: Adverse Events Associated With TKIs in HER2-Mutated NSCLC
    EP. 12: Challenges and Unmet Needs in HER2-Mutated NSCLC
    EP. 13: Treatment Considerations in HER2-Mutated NSCLC
    EP. 14: Key Takeaways in HER2-Mutated NSCLC
    x